Figures computed from official regulatory filings — .
Analysttarget 25 USD (+1453%)
Ownershipinsiders 14.82% · institutions 18.7% · short 0.6% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Processa Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
71 buys19 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Ng George Ktrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ng George Ktrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Gujrathi Sheila | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Gujrathi Sheila | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Pannu Geraldine | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lin Patricktrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Guy Wendytrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ng George Ktrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SKIBSTED RUSSELLtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Baluch Khosotrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Neal James Rtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Yorke Justin W | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ng George Ktrack record | Buy | $5.9K | conv 55Cluster | SEC |
| Lin Patricktrack record | Buy | $4.1K | conv 41Cluster | SEC |
| Guy Wendytrack record | Buy | $4.7K | conv 54Cluster | SEC |
| SKIBSTED RUSSELLtrack record | Buy | $6.3K | conv 53Cluster | SEC |
| Young Davidtrack record | Buy | $4.9K | conv 36Cluster | SEC |
| Yorke Justin W | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Baluch Khosotrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pannu Geraldine | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Baluch Khosotrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Neal James Rtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pannu Geraldine | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Yorke Justin W | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Neal James Rtrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |